Kun Li
Associate Professor
Room 318, Experimental Building A
Email: kli@hsc.ecnu.edu.cn
Brief Biography:
Dr. Kun Li currently serves as an Associate Professor at the Health Science Center, East China Normal University. He graduated from the Shandong Normal University with a Bachelor of Science degree, and received his Ph.D. degree from East China Normal University. He worked as a Postdoc in Department of Musculoskeletal Oncology at Fudan University Shanghai Cancer Center. Dr. Li’s study interests are mainly related to cancer and cardiovascular disease treatment. His research was supported by the Youth Science Fund from the National Natural Science Foundation of China （NSFC）, the Natural Science Foundation of Shanghai ‘Yang Fan Program’ and, the Postdoctoral Foundation of China (Special support). His works mainly published as first/corresponding author (including co-first/corresponding author) in journals such as J Clin Invest (2), Cell Death Dis, and ACS Appl. Mater.
Research Interests:
1. Development of new drug targets and intervention strategies related to amino acid metabolism in tumor；
2. Development of new drug targets and intervention strategies related to amino acid metabolism in cardiovascular diseases such as atherosclerosis and vascular restenosis.
Publications (recent 5 years):
(1) Kun Li#; Yanan Liu#; Yi Ding; Zhengwei Zhang; Juanjuan Feng; Jiaxin Hu; Jiwei Chen; Zhengke Lian; Yiliang Chen; Kewen Hu; Zhi Chen; Zhenyu Cai; Mingyao Liu; Xiufeng Pang*; BCL6 is regulatedby the MAPK/ELK1 axis and promotes KRAS-driven lung cancer, Journal of Clinical Investigation, 2022, 132(22)
(2) Kewen Hu#; Kun Li#; Jing Lv#; Jie Feng; Jing Chen; Haigang Wu; Feixiong Cheng; Wenhao Jiang;Jieqiong Wang; Haixiang Pei; Paul J. Chiao; Zhenyu Cai; Yihua Chen; Mingyao Liu*; Xiufeng Pang* ; Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma, Journal of Clinical Investigation, 2020, 130(4): 1752-1766
(3) Yuchen Qi#, Yangyang Li#, Kun Li#, Tingting Xie, Shiyuan Hua, Qunfeng Guo*, Yichun Zheng*, and Min Zhou* Biocompatible Gallium Nanodots against Drug-Resistant Bacterial Pneumonia and Liver Abscess. ACS Appl Mater Interfaces, 2023. 15(33): 39143-39156.
(4) Yujie Liu#; Ao Leng#; Lin Li#; Bo Yang; Shihui Shen; Hui Chen; Enhao Zhu; Qiyue Xu; Xiaoyu Ma; Peilin Shi; Yun Liu; Tielong Liu; Lei Li; Kun Li*; Dan Zhang*; Jianru Xiao*; AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway, Cell Death & Disease, 2022, 13(3): 288
(5) Jiawei Guo#; Yanan Liu#; Jing Lv; Bin Zou; Zhi Chen; Kun Li; Juanjuan Feng; Zhenyu Cai; Lai Wei; Mingyao Liu; Xiufeng Pang*; BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors, Journal of Clinical Investigation, 2021, 131(1): 133090
(6) JuanJuan Feng#; Wenhao Jiang#; Yanan Liu; Wanfeng Huang; Kewen Hu; Kun Li; Jing Chen; Cheng bin Ma*; Zhenliang Sun*; Xiufeng Pang*; Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS mutant lung cancer, Biochemical Pharmacology, 2020, 177: 113960
https://orcid.org/0000-0002-5863-9865